Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study

Prior treatment

• Patient with contraindication to the study drugs

Other illness

• Patient with history of allergy or hypersensitivity to components of the study drugs

Other

• Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
• Current participation in another clinical study and/or in an investigational program with any intervention that could possibly interfere with the treatment and impact this study
• Pregnant or lactating woman
• Patient unable to use digital tools
• Patient deprived of liberty or placed under the authority of a tutor

• Patient older than 18 years
• Diagnosis of Renal Cell Carcinoma (RCC) with a clear-cell component
• No prior systemic treatment for RCC
• Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, according to approved local labels
• Subjects affiliated to an appropriate social security system
• Patient has signed informed consents obtained before any trial related activities and according to local guidelines